Exhibiting at VIV Asia 2025

Huvepharma EOOD is a globally recognized pharmaceutical and biotechnology company headquartered in Sofia, Bulgaria, specializing in the development, manufacturing, and marketing of animal health and human health products. With a vertically integrated structure and a global commercial presence, Huvepharma is one of the fastest-growing veterinary pharmaceutical companies worldwide, particularly focused on livestock and poultry health solutions.

Core Business Segments

Huvepharma operates across three major business divisions:

• Animal Health:

  • Extensive portfolio of vaccines, antimicrobials, anticoccidials, enzymes, and feed additives tailored for poultry, swine, cattle, aquaculture, and companion animals.
  • Marketed in over 100 countries with a comprehensive range of both prescription and over-the-counter veterinary products.

• Human Health:

  • Specializes in the production of enzymes and active pharmaceutical ingredients (APIs), particularly for gastrointestinal health.
  • Supplies pharmaceutical ingredients to global clients under GMP-certified facilities.

• Nutritional Supplements:

  • Offers a wide array of probiotics, vitamins, and enzymes that enhance animal digestion and immunity.
  • Designed for integration into animal feed to support growth performance and disease resistance.

Manufacturing and Vertical Integration

Huvepharma’s competitive edge lies in its complete control over the value chain:

• Global Manufacturing Footprint:

  • Operates more than 10 production sites across Bulgaria, France, Italy, and the USA.
  • Notable facilities include fermentation plants, formulation sites, and API production centers.

• Fermentation Capacity:

  • Among the largest producers of fermentation-based veterinary APIs in Europe.
  • Over 5,000 cubic meters of fermentation capacity annually.

• GMP & EU Certified:

  • All manufacturing sites are certified under Good Manufacturing Practices (GMP) and EU Veterinary Directives.

R&D and Innovation

• In-house R&D teams work across sites in Europe and North America, with more than 300 scientists dedicated to:

  • New drug development
  • Vaccine innovation
  • Formulation technology
  • Resistance management strategies

• Investment in R&D accounts for over 6% of annual revenue, focused on:

  • Next-gen feed enzyme systems
  • Antibiotic alternatives
  • Disease-prevention tools for global livestock industries

Market Reach and Financial Performance

• Global Operations:

  • Direct commercial presence in over 40 countries
  • Products registered in more than 100 countries

• Major Markets:

  • Europe, North America, Latin America, Middle East, and Asia-Pacific
  • Strategic expansion in Brazil, India, and China

• Revenue Performance:

  • Reported revenue of over €580 million in 2022
  • Consistent double-digit growth over the past five years

• Acquisitions and Expansion:

  • Acquired Biovet and Antelliq assets to expand into biologics and diagnostic tools

Product Portfolio Highlights

• Top Brands and Solutions:

  • Optigrid®, Monovet®, Appertex®, Coxiril®, and Flavomycin®
  • Feed additives and enzyme complexes for performance improvement in poultry and swine
  • Full vaccine programs for coccidiosis, Salmonella, and respiratory diseases

• Innovation Milestones:

  • One of the first EU-approved manufacturers of bacitracin and monensin
  • Developed enzyme blends that reduce environmental impact by lowering nitrogen excretion

Certifications and Regulatory Compliance

• ISO 9001, ISO 14001, ISO 45001
• EU GMP and US FDA-approved facilities for veterinary and human drugs
• Compliant with EFSA, EMA, USDA, and other global regulatory agencies

Sustainability and Biosecurity

• Committed to antimicrobial stewardship
• Focus on reducing antibiotic resistance through vaccine adoption and alternative therapies
• Investments in environmentally sustainable manufacturing, including wastewater recycling and energy optimization

Strategic Vision

Huvepharma's long-term strategy focuses on:

• Strengthening its biologicals and vaccine portfolios
• Expanding further into aquaculture and companion animal segments
• Leading the market in feed enzyme technologies and gut health solutions
• Driving innovation in residue-free food production

With an unwavering focus on science, scale, and sustainability, Huvepharma EOOD continues to be a driving force in global animal and human health advancement.